Enhancing gamma band response to improve working memory in individuals with mild cognitive impairment

增强伽马带反应以改善轻度认知障碍患者的工作记忆

基本信息

批准号：
10599955
负责人：
Fiza Singh
金额：
$ 65.37万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-04-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10599955
关键词：
Accounting Activities of Daily Living Adult Affect Alzheimer&apos s Disease Alzheimer&apos s disease model Alzheimer&apos s disease patient American Amyloid beta-42 Amyloid beta-Protein Amyloid beta-Protein Precursor Animal Model Animals Anxiety Area Attention Attention deficit hyperactivity disorder Back Binding Biological Markers Brain Brain region Butyric Acids Centers for Disease Control and Prevention (U.S.)Characteristics Child Clinical Cognition Cognition Disorders Cognitive deficits Computers Dementia Disease Disease Progression Dose Down Syndrome Early identification Effect Modifiers (Epidemiology)Elderly Electroencephalography Eye Frequencies Genetic Genetic Risk Histopathology Impaired cognition Impairment Individual Interneurons Intervention Mediating Mediator Memory Memory impairment Mental Depression Metaphor Neocortex Neurobiology Neurodegenerative Disorders Neurons Neuropsychological Tests Participant Patients Phase Photic Stimulation Placebos Play Population Prediction of Response to Therapy Prefrontal Cortex Public Health Randomized Reading Reporting Research Research Personnel Risk Risk Factors Role Senile Plaques Short-Term Memory Synaptic plasticity Techniques Testing Training Programs Visual amnestic mild cognitive impairment apolipoprotein E-4 brain based cognitive load cognitive reserve comparison control cost economic impact efficacy testing functional disability high risk hippocampal pyramidal neuron improved indexing mild cognitive impairment multisensory neocortical neural neural circuit neural network neurofeedback neuromechanism neuron loss neuroregulation novel post intervention prevent primary outcome recruit response risk variant secondary outcome tau Proteins tau-1 therapy development treatment response

项目摘要

Abstract Alzheimer’s disease (AD) is the clinical manifestation of a neurodegenerative disorder characterized by pervasive and progressive cognitive decline with impairment in activities of daily living. According to the Centers for Disease Control the number of Americans with Alzheimer’s disease or dementia will grow to 13.9 million (2018 report) by 2060, making it an urgent public concern. Research in the last decade has focused on early identification of the disease and revealed a prodromal phase prior to the onset of functional impairments, known as mild cognitive impairment (MCI). Despite early identification, there are few treatment options to slow down progression from MCI to AD. Recent studies suggest that cognitive deficits may arise from abnormal synchronization of distributed neural networks. Synchronization or synchronous firing of neurons, binds cortical areas into functional networks in a task and state-dependent manner. Specifically, neural synchrony in the gamma band (30-45Hz) plays a central role in top-down attention, multisensory processing, perceptual binding and working memory (WM) in healthy individuals. Gamma band responses (GBR) are impaired in individuals with AD spectrum disorders, and animal studies in AD models targeting GBR have shown positive effects on cognition. Thus, developing similar treatments targeting GBR are expected to improve cognition in individuals with MCI. Our group has administered EEG-neurofeedback (EEG-NFB) targeting GBR in SCZ patients, with promising early results (research strategy). NFB is a low-cost, safe, easily administered closed-loop neuromodulation technique where subjects are shown their brain activity as a visual metaphor and asked to modulate it in a given direction. EEG- NFB has been employed in multiple disorders ranging from ADHD, depression, to anxiety and in multiple populations including children and older adults. Based on these encouraging results, we are proposing a study to 1) test the efficacy of EEG-NFB targeting GBR in individuals with amnestic MCI compared to a sham/placebo, 2) explore the mechanism underlying change in cognition and 3) explore pre-treatment characteristics that predict treatment response.

抽象的阿尔茨海默病（AD）是一种神经退行性疾病的临床表现，其特征是根据该报告，认知能力普遍下降并伴有日常生活活动受损。疾病控制中心称，患有阿尔茨海默病或痴呆症的美国人人数将增至 13.9 人到 2060 年，这一数字将达到 100 万（2018 年报告），这使其成为过去十年研究重点关注的一个紧迫问题。早期识别疾病并揭示功能障碍发生前的前驱期，被称为轻度认知障碍（MCI），尽管可以早期发现，但几乎没有什么治疗方法可以减缓这种情况。最近的研究表明，认知缺陷可能是由异常引起的。分布式神经网络的同步。神经元的同步或同步放电，将皮层区域绑定到任务中的功能网络中具体来说，伽玛波段（30-45Hz）的神经同步起着核心作用。健康人的自上而下注意力、多感觉处理、知觉结合和工作记忆（WM）患有 AD 谱系疾病的个体和动物的伽马带反应 (GBR) 受损。针对 GBR 的 AD 模型研究显示出对认知的积极影响，因此，开发类似的方法。针对 GBR 的治疗有望改善 MCI 患者的认知能力。对 SCZ 患者进行针对 GBR 的脑电图神经反馈 (EEG-NFB)，取得了有希望的早期结果（研究策略） NFB 是一种低成本、安全、易于管理的闭环神经调节技术。受试者以视觉隐喻的形式显示他们的大脑活动，并要求其按照给定的方向进行调节。 NFB 已被用于治疗多种疾病，从多动症、抑郁症到焦虑症，以及多种疾病基于这些令人鼓舞的结果，我们提出一项研究。 1) 测试针对 GBR 的 EEG-NFB 在遗忘性 MCI 个体中的功效与假手术/安慰剂，2）探索认知变化的机制，3）探索治疗前预测治疗反应的特征。